Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX) will present a corporate overview at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on Monday, June 8, 2026 at 8:00 a.m. ET. A live webcast and a replay (for ~180 days) will be available.
Positive
- None.
Negative
- None.
News Market Reaction – PRAX
In the Jun 5 session, PRAX declined 4.06%, reflecting a moderate negative market reaction. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Inducement grants | Neutral | +8.1% | New-hire RSU grants under 2024 Inducement Plan for thirteen employees. |
| Jun 01 | Clinical update | Negative | -23.0% | Vormatrigine POWER1 failed primary endpoint; POWER2 enrollment paused for reassessment. |
| May 07 | Earnings and update | Positive | -1.4% | Q1 2026 results, strong cash position, key NDAs accepted with PDUFA dates. |
| May 05 | Inducement grants | Neutral | +1.4% | RSUs covering 5,420 shares granted to 21 new non-executive employees. |
| May 04 | Earnings date set | Neutral | -1.3% | Announcement of Q1 2026 results date and participation in health care conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent moves mostly aligned with news tone, except for a mild divergence around Q1 2026 earnings.
Over the past month, PRAX has reported Q1 2026 results with key CNS milestones and substantial cash of $1.4 billion, followed by a negative vormatrigine POWER1 readout that led to a -23% reaction. Routine inducement grants and scheduling of earnings and conference appearances have produced smaller directional moves. Against this backdrop, the Goldman Sachs conference appearance extends an active investor-relations cadence following clinical and regulatory updates.
Key Terms
central nervous system (cns) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will be presenting a corporate overview at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 taking place in Miami, FL at the Loews Miami Beach Hotel on Monday, June 8, 2026 at 8:00am ET.
A live webcast of the event will be available through this link. A replay of the event will also be available on Praxis’ “Events and Presentations” website after each event for approximately 180 days.
About Praxis
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and X/Twitter.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576